CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsThe law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and “anticipates commercial launch in late Q3 2026”, representing a delayed launch timeline relative to analyst expectations. Commenting on the release, Stifel Financial Corp. analyst Stephen Wiley noted that “late 3Q26 launch guidance seems somewhat extended.” Leerink Partners analyst Andrew Berens agreed, noting that while the “approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.”On this news, Celcuity’s stock price fell $19.54 per share, or 17.6%, to close at $91.51 per share on July 15, 2026.What Should I Do?At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. Click here to learn more about securities class actions.If you purchased or otherwise acquired Celcuity securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.[LEARN MORE ABOUT THE INVESTIGATION]Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Kirby McInerney LLPLauren Molinaro, Esq.212-699-1171https://www.kmllp.comhttps://securitiesleadplaintiff.com/investigations@kmllp.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260803277948/en/
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsThe law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and “anticipates commercial launch in late Q3 2026”, representing a delayed launch timeline relative to analyst expectations. Commenting on the release, Stifel Financial Corp. analyst Stephen Wiley noted that “late 3Q26 launch guidance seems somewhat extended.” Leerink Partners analyst Andrew Berens agreed, noting that while the “approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness.”On this news, Celcuity’s stock price fell $19.54 per share, or 17.6%, to close at $91.51 per share on July 15, 2026.What Should I Do?At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. Click here to learn more about securities class actions.If you purchased or otherwise acquired Celcuity securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.[LEARN MORE ABOUT THE INVESTIGATION]Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Kirby McInerney LLPLauren Molinaro, Esq.212-699-1171https://www.kmllp.comhttps://securitiesleadplaintiff.com/investigations@kmllp.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260803277948/en/
Celcuity won FDA clearance for breast cancer drug Revtorpyk but pushed launch to late Q3 2026, beyond analyst expectations. 17.6% stock drop signals execution risk; the guidance miss weakens investor confidence in pipeline commercialization pace.
